10x Genomics, Inc. (TXG) Return on equity 2019–2025
10x Genomics, Inc. (TXG) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-5.5%FY2025 · since FY2019: -7.4% → -5.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -5.5% | +20.2 pp |
| FY2024 | -25.7% | +8.7 pp |
| FY2023 | -34.4% | -13.8 pp |
| FY2022 | -20.6% | -13.5 pp |
| FY2021 | -7.1% | +66.3 pp |
| FY2020 | -73.4% | -66.0 pp |
| FY2019 | -7.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice